Myeloproliferative neoplasms (MPN) are a heterogeneous group of clonal hematopoietic stem cell disorders characterized clinically by the proliferation of one or more hematopoietic lineage(s). The classical Philadelphia-chromosome (Ph)-negative MPNs include polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF). The Asian Myeloid Working Group (AMWG) comprises representatives from fifteen Asian centers experienced in the management of MPN. This consensus from the AMWG aims to review the current evidence in the risk stratification and treatment of Ph-negative MPN, to identify management gaps for future improvement, and to offer pragmatic approaches for treatment commensurate with different levels of resources, drug availabilities and reimbursement policies in its constituent regions. The management of MPN should be patient-specific and based on accurate diagnostic and prognostic tools. In patients with PV, ET and early/prefibrotic PMF, symptoms and risk stratification will guide the need for early cytoreduction. In younger patients requiring cytoreduction and in those experiencing resistance or intolerance to hydroxyurea, recombinant interferon-α preparations (pegylated interferon-α 2A or ropeginterferon-α 2b) should be considered. In myelofibrosis, continuous risk assessment and symptom burden assessment are essential in guiding treatment selection. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) in MF should always be based on accurate risk stratification for disease-risk and post-HSCT outcome. Management of classical Ph-negative MPN entails accurate diagnosis, cytogenetic and molecular evaluation, risk stratification, and treatment strategies that are outcome-oriented (curative, disease modification, improvement of quality-of-life).

1. Barbui, T., Thiele, J., Gisslinger, H., Al Ali, G., Harutyunyan, A. S., Vannucchi, A. M., ... & Tefferi, A. (2018). The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: Document summary and in-depth discussion. Blood Cancer Journal, 8(2), Article 15. https://doi.org/10.1038/s41408-018-0054-y
2. Khoury, J. D., Solary, E., Abla, O., Akkari, Y., Alaggio, R., Apperley, J. F., ... & Argyropoulos, K. V. (2022). The 5th edition of the World Health Organization classification of haematolymphoid tumours: Myeloid and histiocytic/dendritic neoplasms. Leukemia, 36(7), 1703–1719. https://doi.org/10.1038/s41375-022-01613-1
3. Spivak, J. L. (2017). Myeloproliferative neoplasms. New England Journal of Medicine, 376(22), 2168–2181. https://doi.org/10.1056/NEJMra1407928
4. Barbui, T., Thiele, J., Gisslinger, H., Vannucchi, A. M., & Tefferi, A. (2016). The 2016 revision of WHO classification of myeloproliferative neoplasms: Clinical and molecular advances. Blood Reviews, 30(6), 453–459. https://doi.org/10.1016/j.blre.2016.06.001
5. Bittencourt, R. I., Vassallo, J., Chauffaille, M. de L., & Spector, N. (2012). Philadelphia-negative chronic myeloproliferative neoplasms. Revista Brasileira de Hematologia e Hemoterapia, 34(2), 140–149. https://doi.org/10.5581/1516-8484.20120037
6. Gong, X., Lu, X., Xiao, X., & Zhou, X. (2014). Clinicopathologic characteristics of prefibrotic-early primary myelofibrosis in Chinese patients. Human Pathology, 45(3), 498–503. https://doi.org/10.1016/j.humpath.2013.10.015
7. Tefferi, A., & Vardiman, J. W. (2008). Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia, 22(1), 14–22. https://doi.org/10.1038/sj.leu.2404981
8. Gangat, N., Caramazza, D., Vaidya, R., George, G., Begna, K., Schwager, S., ... & Tefferi, A. (2011). DIPSS plus: A refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. Journal of Clinical Oncology, 29(4), 392–397. https://doi.org/10.1200/JCO.2010.32.2446
9. Pardanani, A. D., Levine, L. R., Lasho, T., Pikman, Y., Mesa, R. A., Wadleigh, M., ... & Tefferi, A. (2006). MPL515 mutations in myeloproliferative and other myeloid disorders: A study of 1182 patients. Blood, 108(10), 3472–3476. https://doi.org/10.1182/blood-2006-04-018879
10. Hajnalka, A., Tunde, K., Katalin, B., & Cazzola, M. (2014). Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations. Haematologica, 99(7), 1184–1190. https://doi.org/10.3324/haematol.2014.104448
11. Tefferi, A., Lasho, T. L., Finke, C. M., Knudson, R. A., Ketterling, R., Hanson, C. H., ... & Pardanani, A. (2014). CALR versus JAK2 versus MPL-mutated or triple-negative myelofibrosis: Clinical, cytogenetic and molecular comparisons. Leukemia, 28(7), 1472–1477. https://doi.org/10.1038/leu.2014.3
12. Tefferi, A. (2014). Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management. American Journal of Hematology, 89(9), 915–925. https://doi.org/10.1002/ajh.23803
13. Klampfl, T., Gisslinger, H., Harutyunyan, A. S., Nivarthi, H., Rumi, E., Milosevic, J. D., ... & Kralovics, R. (2013). Somatic mutations of calreticulin in myeloproliferative neoplasms. New England Journal of Medicine, 369(25), 2379–2390. https://doi.org/10.1056/NEJMoa1311347
14. Nangalia, J., Massie, C. E., Baxter, E. J., Nice, F. L., Gundem, G., Wedge, D. C., ... & Green, A. R. (2013). Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. New England Journal of Medicine, 369(25), 2391–2405. https://doi.org/10.1056/NEJMoa1312542
15. Rumi, E., Pietra, D., Ferretti, V., Klampfl, T., Harutyunyan, A. S., Milosevic, J. D., ... & Cazzola, M. (2014). JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood, 123(10), 1544–1551. https://doi.org/10.1182/blood-2013-11-539098
16. Cazzola, M., & Kralovics, R. (2014). From Janus kinase 2 to calreticulin: The clinically relevant genomic landscape of myeloproliferative neoplasms. Blood, 123(24), 3714–3719. https://doi.org/10.1182/blood-2014-03-530865
17. Shirane, S., Araki, M., Morishita, S., Edahiro, Y., Sunami, Y., Hironaka, Y., ... & Komatsu, N. (2015). JAK2, CALR, and MPL mutation spectrum in Japanese patients with myeloproliferative neoplasms. Haematologica, 100(2), e46–e48. https://doi.org/10.3324/haematol.2014.115097
18. Rotunno, G., Mannarelli, C., Guglielmelli, P., Vanschoenbeek, K., Pancrazzi, A., Fanelli, T., ... & Vannucchi, A. M. (2014). Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood, 123(10), 1552–1555. https://doi.org/10.1182/blood-2013-11-538983
19. Tefferi, A., Thiele, J., Vannucchi, A. M., & Barbui, T. (2014). An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms. Leukemia, 28(7), 1407–1413. https://doi.org/10.1038/leu.2014.35
20. Cabagnols, X., Favale, F., Pasquier, F., Messaoudi, K., Defour, J. P., Ianotto, J. C., ... & Vainchenker, W. (2016). Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients. Blood, 127(3), 333–342. https://doi.org/10.1182/blood-2015-07-661983
21. Milosevic Feenstra, J. D., Nivarthi, H., Gisslinger, H., Schischlik, Z., Fidler, M., Gisslinger, B., ... & Kralovics, R. (2016). Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms. Blood, 127(3), 325–332. https://doi.org/10.1182/blood-2015-07-661835
22. Wang, Y.-H., Lin, C.-C., Lee, S.-H., Chang, Y.-C., Lin, C.-Y., Lin, S.-F., & Kuo, M.-C. (2020). ASXL1 mutation confers poor prognosis in primary myelofibrosis patients with low JAK2V617F allele burden but not in those with high allele burden. Blood Cancer Journal, 10(10), Article 99. https://doi.org/10.1038/s41408-020-00366-4
23. Yeh, Y. M., Chen, Y. L., Cheng, H. Y., & Lin, S. F. (2010). High percentage of JAK2 exon 12 mutation in Asian patients with polycythemia vera. American Journal of Clinical Pathology, 134(2), 266–270. https://doi.org/10.1309/AJCPLX7ZOBNZE6PT
24. Wu, Z., Zhang, X., Xu, X., Chen, Y., Hu, T., Kang, Z., ... & Fu, R. (2014). The mutation profile of JAK2 and CALR in Chinese Han patients with Philadelphia chromosome-negative myeloproliferative neoplasms. Journal of Hematology & Oncology, 7, Article 48. https://doi.org/10.1186/1756-8722-7-48
25. Gill, H., Leung, G. M. K., Yim, R., Ip, H. W., Lee, P., Zhou, W., ... & Kwong, Y. L. (2020). Myeloproliferative neoplasms treated with hydroxyurea, pegylated interferon alpha-2A or ruxolitinib: Clinicohematologic responses, quality-of-life changes and safety in the real-world setting. Hematology, 25(1), 247–257. https://doi.org/10.1080/16078454.2020.1779261
26. Kuo, M. C., Chuang, W. Y., Chang, H., Lin, T. H., Shih, L. Y., & Dunn, P. (2023). Comparison of clinical and molecular features between patients with essential thrombocythemia and early/prefibrotic primary myelofibrosis presenting with thrombocytosis in Taiwan. American Journal of Clinical Pathology, 159(5), 474–483. https://doi.org/10.1093/ajcp/aqac172
27. Gill, H., Ip, H. W., Yim, R., Lau, J. S., Lee, P., Khong, P. L., ... & Kwong, Y. L. (2018). Next-generation sequencing with a 54-gene panel identified unique mutational profile and prognostic markers in Chinese patients with myelofibrosis. Annals of Hematology, 97(10), 1803–1814. https://doi.org/10.1007/s00277-018-3382-7
28. Kuo, M. C., Lin, T. H., Sun, C. F., Chang, H., Dunn, P., Shih, L. Y., ... & Wang, P. N. (2018). The clinical and prognostic relevance of driver mutations in 203 Taiwanese patients with primary myelofibrosis. Journal of Clinical Pathology, 71(6), 514–521. https://doi.org/10.1136/jclinpath-2017-204783
29. Fu, R., Xuan, M., Zhou, Y., Liu, P., Zhang, L., Zhang, X., ... & Shao, Z. (2014). Analysis of calreticulin mutations in Chinese patients with essential thrombocythemia: Clinical implications in diagnosis, prognosis and treatment. Leukemia, 28(9), 1912–1914. https://doi.org/10.1038/leu.2014.150
30. Tefferi, A., Lasho, T. L., Huang, J., Finke, C. M., Mesa, R. A., Li, C. Y., ... & Pardanani, A. (2008). Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia, 22(4), 756–761. https://doi.org/10.1038/sj.leu.2405124
31. Tefferi, A. (2010). Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia, 24(6), 1128–1138. https://doi.org/10.1038/leu.2010.69
32. Tefferi, A., Lasho, T. L., Finke, C. M., Elala, Y., Hanson, C. A., Ketterling, R. P., ... & Pardanani, A. (2016). Targeted deep sequencing in primary myelofibrosis. Blood Advances, 1(2), 105–111. https://doi.org/10.1182/bloodadvances.2016000786
33. Vannucchi, A. M., Lasho, T. L., Guglielmelli, P., Biamonte, F., Pardanani, A., Pereira, A., ... & Tefferi, A. (2013). Mutations and prognosis in primary myelofibrosis. Leukemia, 27(9), 1861–1869. https://doi.org/10.1038/leu.2013.119
34. Barbui, T., Tefferi, A., Vannucchi, A. M., Passamonti, F., Silver, R. T., Hoffman, R., ... & European LeukemiaNet. (2018). Philadelphia chromosome-negative classical myeloproliferative neoplasms: Revised management recommendations from European LeukemiaNet. Leukemia, 32(5), 1057–1069. https://doi.org/10.1038/s41375-018-0077-1
35. Guglielmelli, P., Pacilli, A., Rotunno, G., Rumi, E., Caramella, M., Maffioli, M., ... & Vannucchi, A. M. (2017). Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis. Blood, 129(24), 3227–3236. https://doi.org/10.1182/blood-2017-01-761999
36. Mesa, R., Miller, C. B., Thyne, M., Corona, G., Santiago-Dieppa, O., Radia, D., ... & Harrison, C. (2016). Myeloproliferative neoplasms (MPNs) have a significant impact on patients’ overall health and productivity: The MPN Landmark survey. BMC Cancer, 16, Article 167. https://doi.org/10.1186/s12885-016-2208-2
37. Yassin, M. A., Taher, A., Mathews, V., Al-Ali, H. K., Shamsi, T. S., Ahmed, A. O., ... & Shafi, F. (2020). MERGE: A multinational, multicenter observational registry for myeloproliferative neoplasms in Asia, including Middle East, Turkey, and Algeria. Cancer Medicine, 9(13), 4512–4526. https://doi.org/10.1002/cam4.2995
38. Oon, S. F., Singh, D., Tan, T. H., Sivasubramaniam, S., & Shivanand, G. (2019). Primary myelofibrosis: Spectrum of imaging features and disease-related complications. Insights into Imaging, 10, Article 71. https://doi.org/10.1186/s13244-019-0759-x
39. Meier, B., & Burton, J. H. (2014). Myeloproliferative disorders. Emergency Medicine Clinics of North America, 32(3), 597–612. https://doi.org/10.1016/j.emc.2014.04.011
40. Duangnapasatit, B., Rattarittamrong, E., Rattanathammethee, T., Chai-Adisaksopha, C., & Tantiworawit, A. (2015). Clinical manifestations and risk factors for complications of Philadelphia chromosome-negative myeloproliferative neoplasms. Asian Pacific Journal of Cancer Prevention, 16(12), 5013–5018. https://doi.org/10.7314/APJCP.2015.16.12.5013
41. Tefferi, A., & Barbui, T. (2020). Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management. American Journal of Hematology, 95(12), 1599–1613. https://doi.org/10.1002/ajh.26008
42. Spivak, J. L. (2018). Polycythemia vera. Current Treatment Options in Oncology, 19(2), Article 12. https://doi.org/10.1007/s11864-018-0527-y
43. Cuthbert, D., & Stein, B. L. (2019). Polycythemia vera-associated complications: Pathogenesis, clinical manifestations, and effects on outcomes. Journal of Blood Medicine, 10, 359–371. https://doi.org/10.2147/JBM.S189922
44. Siegel, F. P., Tauscher, J., & Petrides, P. E. (2013). Aquagenic pruritus in polycythemia vera: Characteristics and influence on quality of life in 441 patients. American Journal of Hematology, 88(8), 665–669. https://doi.org/10.1002/ajh.23474
45. Denman, M., Szur, L., & Ansell, B. M. (1966). Hyperuricaemia in polycythaemia vera. Annals of the Rheumatic Diseases, 25(4), 340–344. https://doi.org/10.1136/ard.25.4.340
46. Murakami, J., & Shimizu, Y. (2013). Hepatic manifestations in hematological disorders. International Journal of Hepatology, 2013, Article 484903. https://doi.org/10.1155/2013/484903
47. Emanuel, R. M., Dueck, A. C., Geyer, H. L., Kiladjian, J. J., Slot, S., Cannella, L., ... & Mesa, R. A. (2012). Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: Prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. Journal of Clinical Oncology, 30(33), 4098–4103. https://doi.org/10.1200/JCO.2012.42.3863
48. Mesa, R. A., Niblack, J., Wadleigh, M., Verstovsek, S., Camoriano, J., Barnes, S., ... & Tefferi, A. (2007). The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): An international Internet-based survey of 1179 MPD patients. Cancer, 109(1), 68–76. https://doi.org/10.1002/cncr.22365
49. Scherber, R., Dueck, A. C., Johansson, P., Kiladjian, J. J., Slot, S., Libedinsky, C., ... & Mesa, R. A. (2011). The myeloproliferative neoplasm symptom assessment form (MPN-SAF): International prospective validation and reliability trial in 402 patients. Blood, 118(2), 401–408. https://doi.org/10.1182/blood-2011-01-328955
50. Spivak, J. L. (2019). How I treat polycythemia vera. Blood, 134(4), 341–352. https://doi.org/10.1182/blood.2018834044
51. Tefferi, A., & Barbui, T. (2023). Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management. American Journal of Hematology, 98(9), 1465–1487. https://doi.org/10.1002/ajh.27002
52. Najean, Y., Arrago, J. P., Rain, J. D., & Dresch, C. (1984). The ‘spent’ phase of polycythaemia vera: Hypersplenism in the absence of myelofibrosis. British Journal of Haematology, 56(1), 163–170. https://doi.org/10.1111/j.1365-2141.1884.tb03943.x
53. Mossuz, P., Girodon, F., Donnard, M., Latger-Cannard, V., Dobo, I., Boiret, N., ... & Praloran, V. (2004). Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis. Haematologica, 89(10), 1194–1198.
54. Messinezy, M., Westwood, N. B., El-Hemaidi, I., Strong, R. M., & Pearson, T. C. (2002). Serum erythropoietin values in erythrocytoses and in primary thrombocythaemia. British Journal of Haematology, 117(1), 47–53. https://doi.org/10.1046/j.1365-2141.2002.03378.x
55. Tefferi, A. (1999). Diagnosing polycythemia vera: A paradigm shift. Mayo Clinic Proceedings, 74(2), 159–162. https://doi.org/10.4065/74.2.159
56. Lupak, O., Han, X., Xie, P., & Elkin, R. (2020). The role of a low erythropoietin level for the polycythemia vera diagnosis. Blood Cells, Molecules, and Diseases, 80, Article 102355. https://doi.org/10.1016/j.bcmd.2019.102355
57. Shih, L. Y., Lee, C. T., See, L. C., & Dunn, P. (1998). In vitro culture growth of erythroid progenitors and serum erythropoietin assay in the differential diagnosis of polycythaemia. European Journal of Clinical Investigation, 28(7), 569–576. https://doi.org/10.1046/j.1365-2362.1998.00318.x
58. Millard, F. E., Hunter, C. S., Anderson, M., Laszlo, J., & Weinberg, J. B. (1990). Clinical manifestations of essential thrombocythemia in young adults. American Journal of Hematology, 33(1), 27–31. https://doi.org/10.1002/ajh.2830330106
59. Chuzi, S., & Stein, B. L. (2017). Essential thrombocythemia: A review of the clinical features, diagnostic challenges, and treatment modalities in the era of molecular discovery. Leukemia & Lymphoma, 58(12), 2786–2798. https://doi.org/10.1080/10428194.2017.1312371
60. Barzilai, M., Kirgner, I., Ellis, M., Shvidel, L., Tavor, S., Ruchlemer, R., ... & Varon, D. (2017). Characteristics and outcome of Philadelphia(Ph) negative myeloproliferative neoplasms(MPN) in patients younger than 45 years - A multicenter retrospective study. Blood, 130(Suppl 1), Article 2917. https://doi.org/10.1182/blood.V130.Suppl_1.2917.2917
61. Tefferi, A. (2023). Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management. American Journal of Hematology, 98(5), 801–821. https://doi.org/10.1002/ajh.26888
62. Palandri, F., Breccia, M., Bonifacio, M., Iurlo, A., Gambacorti-Passerini, C., Abruzzese, E., ... & Benevolo, G. (2020). Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. Cancer, 126(6), 1243–1252. https://doi.org/10.1002/cncr.32665
63. Iurlo, A., Cattaneo, D., & Gianelli, U. (2019). Blast transformation in myeloproliferative neoplasms: Risk factors, biological findings, and targeted therapeutic options. International Journal of Molecular Sciences, 20(8), Article 1839. https://doi.org/10.3390/ijms20081839
64. Suleiman, Y., Dalia, S., Liu, J., Gergis, U., & Pinilla-Ibarz, J. (2014). Clinical prognostic factors and outcomes of essential thrombocythemia when transformed to myelodysplastic syndrome and acute myeloid leukemia. Blood, 124(21), Article 1821. https://doi.org/10.1182/blood.V124.21.1821.1821
65. Yogarajah, M., & Tefferi, A. (2017). Leukemic transformation in myeloproliferative neoplasms: A literature review on risk, characteristics, and outcome. Mayo Clinic Proceedings, 92(7), 1118–1128. https://doi.org/10.4065/mcp.2017.0177
66. Abdulkarim, K., Girodon, F., Johansson, P., Maynadié, M., Kutti, J., Carli, P. M., ... & Andréasson, B. (2009). AML transformation in 56 patients with Ph- MPD in two well defined populations. European Journal of Haematology, 82(2), 106–111. https://doi.org/10.1111/j.1600-0609.2008.01162.x
67. Cervantes, F., Tassies, D., Salgado, C., Rovira, M., Pereira, A., & Rozman, C. (1991). Acute transformation in nonleukemic chronic myeloproliferative disorders: Actuarial probability and main characteristics in a series of 218 patients. Acta Haematologica, 85(3), 124–127. https://doi.org/10.1159/000205037
68. Tam, C. S., Nussenzveig, R. M., Popat, U., Bueso-Ramos, C. E., Thomas, D. A., Cortes, J. A., ... & Verstovsek, S. (2008). The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms. Blood, 112(5), 1628–1637. https://doi.org/10.1182/blood-2008-02-138230
69. Tefferi, A., Rumi, E., Finazzi, G., Elena, C., Porta, M. G. D., Boveri, E., ... & Barbui, T. (2013). Survival and prognosis among 1545 patients with contemporary polycythemia vera: An international study. Leukemia, 27(9), 1874–1881. https://doi.org/10.1038/leu.2013.163
70. Barbui, T., Thiele, J., Passamonti, F., Rumi, E., Boveri, E., Ruggeri, M., ... & Tefferi, A. (2011). Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: An international study. Journal of Clinical Oncology, 29(23), 3179–3184. https://doi.org/10.1200/JCO.2010.34.5298
71. Vardiman, J. W., Thiele, J., Arber, D. A., Brunning, R. D., Borowitz, M. J., Porwit, A., ... & Bloomfield, C. D. (2009). The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood, 114(5), 937–951. https://doi.org/10.1182/blood-2009-03-209262
72. Tefferi, A., Guglielmelli, P., Larson, D. R., Finke, C. M., Wassie, E. A., Pieri, L., ... & Vannucchi, A. M. (2014). Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood, 124(16), 2507–2513. https://doi.org/10.1182/blood-2014-05-575340
73. Visser, O., Trama, A., Maynadié, M., Willemze, R., Lesoor, M., De Angelis, R., ... & EUROCARE Working Group. (2012). Incidence, survival and prevalence of myeloid malignancies in Europe. European Journal of Cancer, 48(17), 3257–3266. https://doi.org/10.1016/j.ejca.2012.05.024
74. Noone, A. M., Howlader, N., Krapcho, M., Miller, D., Brest, A., Yu, M., ... & Cronin, K. A. (Eds.). (2018). SEER Cancer Statistics Review, 1975–2015. National Cancer Institute.
75. Byun, J. M., Kim, Y. J., Youk, T., Yang, M. S., Choi, K. S., & Park, S. (2017). Real world epidemiology of myeloproliferative neoplasms: A population based study in Korea 2004–2013. Annals of Hematology, 96(3), 373–381. https://doi.org/10.1007/s00277-016-2882-7
76. Lim, Y., Lee, J.-O., & Bang, S.-M. (2016). Incidence, survival and prevalence statistics of classical myeloproliferative neoplasm in Korea. Journal of Korean Medical Science, 31(10), 1579–1585. https://doi.org/10.3346/jkms.2016.31.10.1579
77. Mehta, J., Wang, H., Iqbal, S. U., & Mesa, R. (2014). Epidemiology of myeloproliferative neoplasms in the United States. Leukemia & Lymphoma, 55(3), 595–600. https://doi.org/10.3109/10428194.2013.813500
78. Moulard, O., Mehta, J., Fryzek, J., Matchaba, R., & Sireci, T. (2014). Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union. European Journal of Haematology, 92(4), 289–297. https://doi.org/10.1111/ejh.12233
79. Yap, Y. Y., Law, K. B., Sathar, J., Perry, E., Chew, L. P., Goh, A. S., ... & Ong, T. C. (2018). The epidemiology and clinical characteristics of myeloproliferative neoplasms in Malaysia. Experimental Hematology & Oncology, 7, Article 31. https://doi.org/10.1186/s40164-018-0123-5
80. Kanitsap, N. (2019). A 12-year retrospective study of myeloproliferative neoplasm patients at Thammasat Hospital. Thammasat Medical Journal, 19(2), 285–296.
81. Gill, H., Leung, A. Y. H., Chan, C.-C., Lau, J. S. M., Ip, H. W., Liang, R., & Kwong, Y. L. (2016). Clinicopathologic features and prognostic indicators in Chinese patients with myelofibrosis. Hematology, 21(1), 10–18. https://doi.org/10.1179/1607845415Y.0000000030
82. Chia, P. S., Chong, V. C., Tay, T. Y., Ong, K. H., Tan, D., & Lee, S. Y. (2018). Epidemiology of patients with classical Philadelphia-chromosome negative myeloproliferative neoplasms at a single academic medical center in Singapore. Blood, 132(Suppl 1), Article 5478. https://doi.org/10.1182/blood-2018-99-114407
83. Mesa, R. A., Jamieson, C., Bhatia, R., Deininger, M. W., Fletcher, C. D., Gerds, A. T., ... & National Comprehensive Cancer Network. (2017). NCCN guidelines insights: Myeloproliferative neoplasms, version 2.2018. Journal of the National Comprehensive Cancer Network, 15(10), 1193–1207. https://doi.org/10.6004/jnccn.2017.0157
84. Kröger, N. M., Deeg, J. H., Olavarria, E., Niederwieser, D., Bacigalupo, A., Barbui, T., ... & EBMT/ELN International Working Group. (2015). Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: A consensus process by an EBMT/ELN international working group. Leukemia, 29(11), 2126–2133. https://doi.org/10.1038/leu.2015.89
85. Vannucchi, A. M., Barbui, T., Cervantes, F., Harrison, C., Kiladjian, J. J., Kröger, N., ... & ESMO Guidelines Committee. (2015). Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 26(Suppl 5), v85–v99. https://doi.org/10.1093/annonc/mdv203
86. Reilly, J. T., McMullin, M. F., Beer, P. A., Butt, N., Conneally, E., Devereux, S., ... & Harrison, C. N. (2014). Use of JAK inhibitors in the management of myelofibrosis: A revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012. British Journal of Haematology, 167(3), 418–420. https://doi.org/10.1111/bjh.13009
87. Reilly, J. T., McMullin, M. F., Beer, P. A., Butt, N., Conneally, E., Green, A. R., ... & British Committee for Standards in Haematology. (2012). Guideline for the diagnosis and management of myelofibrosis. British Journal of Haematology, 158(4), 453–471. https://doi.org/10.1111/j.1365-2141.2012.09179.x
88. McMullin, M. F., Harrison, C. N., Ali, S., Cargo, C., Green, A. R., ... & British Society for Haematology. (2019). A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology Guideline. British Journal of Haematology, 184(2), 176–191. https://doi.org/10.1111/bjh.15648
89. Yoon, D. H., Cao, J., Chen, T.-Y., Izutsu, K., Kim, S. J., Kwong, Y. L., ... & Suh, C. (2020). Treatment of mantle cell lymphoma in Asia: A consensus paper from the Asian Lymphoma Study Group. Journal of Hematology & Oncology, 13, Article 21. https://doi.org/10.1186/s13045-020-00851-x
90. Yeoh, A. E., Tan, D., Li, C. K., Hori, H., Tse, E., Pui, C. H., ... & Asian Oncology Summit. (2013). Management of adult and paediatric acute lymphoblastic leukaemia in Asia: Resource-stratified guidelines from the Asian Oncology Summit 2013. The Lancet Oncology, 14(12), e508–e523. https://doi.org/10.1016/S1470-2045(13)70438-6
91. Tan, D., Tan, S. Y., Lim, S. T., ... & Asian Oncology Summit. (2013). Management of B-cell non-Hodgkin lymphoma in Asia: Resource-stratified guidelines. The Lancet Oncology, 14(12), e548–e561. https://doi.org/10.1016/S1470-2045(13)70439-8
92. Mesina, F., & Castillo, M. R. I. D. (2014). Clinical profile and survival of Filipino myelofibrosis patients seen in a tertiary hospital. Philippine Journal of Internal Medicine, 52(1), 1–6.
93. Gong, Z., Medeiros, L. J., Cortes, J. E., ... & Bueso-Ramos, C. E. (2017). Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy. Blood Advances, 1(26), 2541–2552. https://doi.org/10.1182/bloodadvances.2017011684
94. Alvarez-Larrán, A., Angona, A., Ancochea, A., ... & Besses, C. (2016). Masked polycythaemia vera: Presenting features, response to treatment and clinical outcomes. European Journal of Haematology, 96(1), 83–89. https://doi.org/10.1111/ejh.12551
95. Barbui, T., Thiele, J., Gisslinger, H., ... & Tefferi, A. (2017). Diagnostic impact of the 2016 revised WHO criteria for polycythemia vera. American Journal of Hematology, 92(5), 417–419. https://doi.org/10.1002/ajh.24683
96. Tefferi, A., & Barbui, T. (2017). Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management. American Journal of Hematology, 92(1), 94–108. https://doi.org/10.1002/ajh.24607
97. Marchioli, R., Finazzi, G., Specchia, G., ... & CYTO-PV Collaborative Group. (2013). Cardiovascular events and intensity of treatment in polycythemia vera. New England Journal of Medicine, 368(1), 22–33. https://doi.org/10.1056/NEJMoa1208565
98. Lussana, F., Carobbio, A., Randi, M. L., ... & Barbui, T. (2014). A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera. British Journal of Haematology, 167(4), 541–546. https://doi.org/10.1111/bjh.13069
99. Barbui, T., Carobbio, A., Rumi, E., ... & Vannucchi, A. M. (2014). In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. Blood, 124(19), 3021–3023. https://doi.org/10.1182/blood-2014-07-591610
100. Jeryczynski, G., Thiele, J., Gisslinger, B., ... & Gisslinger, H. (2017). Pre-fibrotic/early primary myelofibrosis versus WHO-defined essential thrombocythemia: The impact of minor clinical diagnostic criteria on the outcome of the disease. American Journal of Hematology, 92(9), 885–891. https://doi.org/10.1002/ajh.24790
101. Gisslinger, H., Jeryczynski, G., Gisslinger, B., ... & Thiele, J. (2016). Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: Comparison between the BCSH and the WHO criteria. Leukemia, 30(5), 1126–1132. https://doi.org/10.1038/leu.2015.352
102. Thiele, J., Kvasnicka, H. M., Müllauer, L., ... & Gisslinger, H. (2011). Essential thrombocythemia versus early primary myelofibrosis: A multicenter study to validate the WHO classification. Blood, 117(21), 5710–5718. https://doi.org/10.1182/blood-2010-10-312108
103. Barbui, T., Barosi, G., Birgegard, G., ... & European LeukemiaNet. (2011). Philadelphia-negative classical myeloproliferative neoplasms: Critical concepts and management recommendations from European LeukemiaNet. Journal of Clinical Oncology, 29(6), 761–770. https://doi.org/10.1200/JCO.2010.31.8436
104. Campbell, P. J., Scott, L. M., Buck, G., ... & United Kingdom National Cancer Research Institute Myeloproliferative Disorders Working Group. (2005). Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: A prospective study. The Lancet, 366(9501), 1945–1953. https://doi.org/10.1016/S0140-6736(05)67785-9
105. Arber, D. A., Orazi, A., Hasserjian, R., ... & Bloomfield, C. D. (2016). The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood, 127(20), 2391–2405. https://doi.org/10.1182/blood-2016-03-643544
106. Barbui, T., Thiele, J., Vannucchi, A. M., & Tefferi, A. (2015). Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis. Blood Cancer Journal, 5(8), e337. https://doi.org/10.1038/bcj.2015.64
107. Busque, L., Porwit, A., Day, R., ... & Canadian MPN Group. (2016). Laboratory investigation of myeloproliferative neoplasms (MPNs): Recommendations of the Canadian MPN group. American Journal of Clinical Pathology, 146(4), 408–422. https://doi.org/10.1093/ajcp/aqw127
108. Barosi, G., Mesa, R., Thiele, J., ... & International Working Group for Myelofibrosis Research and Treatment. (2008). Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia, 22(2), 437–438. https://doi.org/10.1038/sj.leu.2404914
109. Arber, D. A., Orazi, A., Hasserjian, R. P., ... & International Consensus Classification approach. (2022). International consensus classification of myeloid neoplasms and acute leukemias: Integrating morphologic, clinical, and genomic data. Blood, 140(11), 1200–1228. https://doi.org/10.1182/blood.2022015850
110. Arber, D. A., Hasserjian, R. P., Orazi, A., ... & Thiele, J. (2022). Classification of myeloid neoplasms/acute leukemia: Global perspectives and the international consensus classification approach. American Journal of Hematology, 97(5), 514–518. https://doi.org/10.1002/ajh.26512
111. Gerds, A. T., Gotlib, J., Ali, H., ... & National Comprehensive Cancer Network. (2022). Myeloproliferative neoplasms, version 3.2022, NCCN clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network, 20(9), 1033–1062. https://doi.org/10.6004/jnccn.2022.0047
112. Finazzi, G. (2004). A prospective analysis of thrombotic events in the European Collaboration Study on Low-Dose Aspirin in Polycythemia (ECLAP). Pathologie Biologie (Paris), 52(5), 285–288. https://doi.org/10.1016/j.patbio.2004.01.002
113. Landolfi, R., Di Gennaro, L., Barbui, T., ... & European Collaboration Study on Low-Dose Aspirin in Polycythemia (ECLAP). (2007). Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood, 109(6), 2446–2452. https://doi.org/10.1182/blood-2006-08-042515
114. Barbui, T., Masciulli, A., Marfisi, M. R., ... & CYTO-PV Study. (2015). White blood cell counts and thrombosis in polycythemia vera: A subanalysis of the CYTO-PV study. Blood, 126(4), 560–561. https://doi.org/10.1182/blood-2015-04-638627
115. Barbui, T., Finazzi, G., Carobbio, A., ... & Vannucchi, A. M. (2012). Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood, 120(26), 5128–5133. https://doi.org/10.1182/blood-2012-08-447037
116. Barbui, T., Vannucchi, A. M., Buxhofer-Ausch, V., ... & Tefferi, A. (2015). Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia. Blood Cancer Journal, 5(11), e369. https://doi.org/10.1038/bcj.2015.94
117. Haider, M., Gangat, N., Lasho, T., ... & Tefferi, A. (2016). Validation of the revised international prognostic score of thrombosis for essential thrombocythemia (IPSET-thrombosis) in 585 Mayo Clinic patients. American Journal of Hematology, 91(4), 390–394. https://doi.org/10.1002/ajh.24294
118. Cervantes, F., Dupriez, B., Pereira, A., ... & International Working Group for Myelofibrosis Research and Treatment. (2009). New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood, 113(13), 2895–2901. https://doi.org/10.1182/blood-2008-07-169177
119. Passamonti, F., Cervantes, F., Vannucchi, A. M., ... & IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). (2010). A dynamic prognostic model to predict survival in primary myelofibrosis: A study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood, 115(9), 1703–1708. https://doi.org/10.1182/blood-2009-09-245837
120. Hussein, K., Pardanani, A. D., Van Dyke, D. L., ... & Tefferi, A. (2010). International prognostic scoring system-independent cytogenetic risk categorization in primary myelofibrosis. Blood, 115(3), 496–499. https://doi.org/10.1182/blood-2009-08-237420
121. Caramazza, D., Begna, K. H., Gangat, N., ... & Tefferi, A. (2011). Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: A single center study of 433 patients. Leukemia, 25(1), 82–88. https://doi.org/10.1038/leu.2010.234
122. Tefferi, A., Siragusa, S., Hussein, K., ... & Pardanani, A. (2010). Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis—Prognostic relevance is independent of IPSS or karyotype. American Journal of Hematology, 85(1), 14–17. https://doi.org/10.1002/ajh.21557
123. Elena, C., Passamonti, F., Rumi, E., ... & Cazzola, M. (2011). Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS. Haematologica, 96(1), 167–170. https://doi.org/10.3324/haematol.2010.031914
124. Patnaik, M. M., Caramazza, D., Gangat, N., ... & Tefferi, A. (2010). Age and platelet count are IPSS-independent prognostic factors in young patients with primary myelofibrosis and complement IPSS in predicting very long or very short survival. European Journal of Haematology, 84(2), 105–108. https://doi.org/10.1111/j.1600-0609.2009.01358.x
125. Tefferi, A., Guglielmelli, P., Nicolosi, M., ... & Vannucchi, A. M. (2018). GIPSS: Genetically inspired prognostic scoring system for primary myelofibrosis. Leukemia, 32(7), 1631–1642. https://doi.org/10.1038/s41375-018-0107-z
126. Guglielmelli, P., Lasho, T. L., Rotunno, G., ... & Tefferi, A. (2018). MIPSS70: Mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis. Journal of Clinical Oncology, 36(4), 310–318. https://doi.org/10.1200/JCO.2017.76.4886
127. Tefferi, A., Guglielmelli, P., Lasho, T. L., ... & Vannucchi, A. M. (2018). MIPSS70+ version 2.0: Mutation and karyotype-enhanced international prognostic scoring system for primary myelofibrosis. Journal of Clinical Oncology, 36(17), 1769–1770. https://doi.org/10.1200/JCO.2018.78.9867
128. Passamonti, F., Giorgino, T., Mora, B., ... & IWG-MRT. (2017). A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. Leukemia, 31(12), 2726–2731. https://doi.org/10.1038/leu.2017.169
129. Landolfi, R., Marchioli, R., Kutti, J., ... & European Collaboration Study on Low-Dose Aspirin in Polycythemia Vera Investigators. (2004). Efficacy and safety of low-dose aspirin in polycythemia vera. New England Journal of Medicine, 350(2), 114–124. https://doi.org/10.1056/NEJMoa035572
130. Hernández-Boluda, J. C., & Gómez, M. (2015). Target hematologic values in the management of essential thrombocythemia and polycythemia vera. European Journal of Haematology, 94(1), 4–11. https://doi.org/10.1111/ejh.12423
131. Tefferi, A., & Barbui, T. (2019). Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management. American Journal of Hematology, 94(1), 133–143. https://doi.org/10.1002/ajh.25300
132. Bose, P., & Verstovsek, S. (2019). Updates in the management of polycythemia vera and essential thrombocythemia. Therapeutic Advances in Hematology, 10, Article 204062071987005. https://doi.org/10.1177/2040620719870052
133. Paranagama, D., Colucci, P., Evans, K. A., ... & Mesa, R. (2018). Are patients with high-risk polycythemia vera receiving cytoreductive medications? A retrospective analysis of real-world data. Experimental Hematology & Oncology, 7, 1–6. https://doi.org/10.1186/s40164-018-0104-8
134. Mancuso, S., Santoro, M., Accurso, V., ... & Siragusa, S. (2020). Cardiovascular risk in polycythemia vera: Thrombotic risk and survival: Can cytoreductive therapy be useful in patients with low-risk polycythemia vera with cardiovascular risk factors? Oncology Research and Treatment, 43(10), 526–530. https://doi.org/10.1159/000509618
135. Marchetti, M., Vannucchi, A. M., Griesshammer, M., ... & European LeukemiaNet. (2022). Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations. The Lancet Haematology, 9(4), e301–e311. https://doi.org/10.1016/S2352-3026(22)00046-1
136. Sankar, K., & Stein, B. L. (2018). Do all patients with polycythemia vera or essential thrombocythemia need cytoreduction? Journal of the National Comprehensive Cancer Network, 16(12), 1539–1545. https://doi.org/10.6004/jnccn.2018.7099
137. Gisslinger, H., Klade, C., Georgiev, P., ... & PROUD-PV and CONTINUATION-PV Study Group. (2020). Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): A randomised, non-inferiority, phase 3 trial and its extension study. The Lancet Haematology, 7(3), e196–e208. https://doi.org/10.1016/S2352-3026(19)30236-4
138. Antonioli, E., Guglielmelli, P., Pieri, L., ... & Vannucchi, A. M. (2012). Hydroxyurea-related toxicity in 3,411 patients with Ph’-negative MPN. American Journal of Hematology, 87(5), 552–554. https://doi.org/10.1002/ajh.23160
139. Ferrari, A., Carobbio, A., Masciulli, A., ... & Barbui, T. (2019). Clinical outcomes under hydroxyurea treatment in polycythemia vera: A systematic review and meta-analysis. Haematologica, 104(12), 2391–2399. https://doi.org/10.3324/haematol.2018.212621
140. Björkholm, M., Derolf, Å. R., Hultcrantz, M., ... & Goldstone, A. H. (2011). Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms. Journal of Clinical Oncology, 29(17), 2410–2415. https://doi.org/10.1200/JCO.2010.34.4077
141. Demuynck, T., Verhoef, G., & Delforge, M. (2019). Polycythemia vera and hydroxyurea resistance/intolerance: A monocentric retrospective analysis. Annals of Hematology, 98(6), 1421–1426. https://doi.org/10.1007/s00277-019-03657-3
142. Malato, A., Rossi, E., Palumbo, G. A., ... & Sabattini, E. (2020). Drug-related cutaneous adverse events in Philadelphia chromosome-negative myeloproliferative neoplasms: A literature review. International Journal of Molecular Sciences, 21(11), Article 3900. https://doi.org/10.3390/ijms21113900
143. Masarova, L., Yin, C. C., Cortes, J. E., ... & Verstovsek, S. (2017). Histomorphological responses after therapy with pegylated interferon α-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV). Experimental Hematology & Oncology, 6, 1–13. https://doi.org/10.1186/s40164-017-0082-x
144. How, J., & Hobbs, G. (2020). Use of interferon alfa in the treatment of myeloproliferative neoplasms: Perspectives and review of the literature. Cancers, 12(7), Article 1954. https://doi.org/10.3390/cancers12071954
145. Yacoub, A., Mascarenhas, J., Kosiorek, H., ... & Silver, R. T. (2019). Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea. Blood, 134(18), 1498–1509. https://doi.org/10.1182/blood.2019000428
146. Quintás-Cardama, A., Kantarjian, H., Manshouri, T., ... & Verstovsek, S. (2009). Pegylated interferon Alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. Journal of Clinical Oncology, 27(32), 5418–5424. https://doi.org/10.1200/JCO.2009.23.6018
147. Quintás-Cardama, A., Abdel-Wahab, O., Manshouri, T., ... & Verstovsek, S. (2013). Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a. Blood, 122(6), 893–901. https://doi.org/10.1182/blood-2012-07-442004
148. Gisslinger, H., Zagrijtschuk, O., Buxhofer-Ausch, V., ... & Klade, C. (2015). Ropeginterferon alfa-2b, a novel IFNalpha-2b, induces high response rates with low toxicity in patients with polycythemia vera. Blood, 126(15), 1762–1769. https://doi.org/10.1182/blood-2015-01-622662
149. Vannucchi, A. M., Kiladjian, J. J., Griesshammer, M., ... & RESPONSE Study Investigators. (2015). Ruxolitinib versus standard therapy for the treatment of polycythemia vera. New England Journal of Medicine, 372(5), 426–435. https://doi.org/10.1056/NEJMoa1409002
150. Griesshammer, M., Saydam, G., Palandri, F., ... & RESPONSE-2 Investigators. (2018). Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial. Annals of Hematology, 97(9), 1591–1600. https://doi.org/10.1007/s00277-018-3326-2
151. Hasselbalch, H. C., & Bjorn, M. E. (2015). Ruxolitinib versus standard therapy for the treatment of polycythemia vera. New England Journal of Medicine, 372(17), 1670. https://doi.org/10.1056/NEJMc1502446
152. Passamonti, F., Griesshammer, M., Palandri, F., ... & RESPONSE-2 Investigators. (2017). Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): A randomised, open-label, phase 3b study. The Lancet Oncology, 18(1), 88–99. https://doi.org/10.1016/S1470-2045(16)30558-1
153. Verstovsek, S., Vannucchi, A. M., Griesshammer, M., ... & RESPONSE Investigators. (2016). Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial. Haematologica, 101(7), 821–829. https://doi.org/10.3324/haematol.2016.143644
154. Kiladjian, J.-J., Winton, E. F., Talpaz, M., & Verstovsek, S. (2015). Ruxolitinib for the treatment of patients with polycythemia vera. Expert Review of Hematology, 8(4), 391–401. https://doi.org/10.1586/17474086.2015.1051460
155. Parasuraman, S., DiBonaventura, M., Reith, K., ... & Paranagama, D. (2015). Patterns of hydroxyurea use and clinical outcomes among patients with polycythemia vera in real-world clinical practice: A chart review. Experimental Hematology & Oncology, 5, 1–10. https://doi.org/10.1186/s40164-016-0032-4
156. Mascarenhas, J., Mesa, R., Prchal, J., & Hoffman, R. (2014). Optimal therapy for polycythemia vera and essential thrombocythemia can only be determined by the completion of randomized clinical trials. Haematologica, 99(6), 945–949. https://doi.org/10.3324/haematol.2014.104430
157. Kuriakose, E. T., Gjoni, S., Wang, Y. L., ... & Silver, R. T. (2013). JAK2V617F allele burden is reduced by busulfan therapy: A new observation using an old drug. Haematologica, 98(10), e135–e137. https://doi.org/10.3324/haematol.2013.093484
158. Alvarez-Larrán, A., Martínez-Avilés, L., Hernández-Boluda, J. C., ... & Besses, C. (2014). Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea. Annals of Hematology, 93(12), 2037–2043. https://doi.org/10.1007/s00277-014-2155-8
159. Forsyth, C. J., Chan, W. H., Grigg, A. P., ... & Classical MPN Working Group. (2019). Recommendations for the use of pegylated interferon-α in the treatment of classical myeloproliferative neoplasms. Internal Medicine Journal, 49(8), 948–954. https://doi.org/10.1111/imj.14241
160. Kiladjian, J. J., Chomienne, C., & Fenaux, P. (2008). Interferon-α therapy in bcr-abl-negative myeloproliferative neoplasms. Leukemia, 22(11), 1990–1998. https://doi.org/10.1038/leu.2008.232
161. Alvarez-Larrán, A., Pereira, A., Cervantes, F., ... & Besses, C. (2012). Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera. Blood, 119(6), 1363–1369. https://doi.org/10.1182/blood-2011-10-387787
162. Alvarez-Larrán, A., Sant’Antonio, E., Harrison, C., ... & European LeukemiaNet. (2021). Unmet clinical needs in the management of CALR-mutated essential thrombocythaemia: A consensus-based proposal from the European LeukemiaNet. The Lancet Haematology, 8(9), e658–e665. https://doi.org/10.1016/S2352-3026(21)00206-8
163. Sarma, A., McLornan, D., & Harrison, C. N. (2017). Spotlight on anagrelide hydrochloride for the treatment of essential thrombocythemia. Orphan Drugs: Research and Reviews, 7, 11–23. https://doi.org/10.2147/ODRR.S106202
164. Galvez, C., & Stein, B. L. (2020). Thrombocytosis and thrombosis: Is there really a correlation? Current Hematology Malignancy Reports, 15(4), 261–267. https://doi.org/10.1007/s11899-020-00588-w
165. Espasandin, Y. R., Glembotsky, A. C., Grodzielski, M., ... & Heller, P. G. (2015). Anagrelide platelet-lowering effect is due to inhibition of both megakaryocyte maturation and proplatelet formation: Insight into potential mechanisms. Journal of Thrombosis and Haemostasis, 13(4), 631–642. https://doi.org/10.1111/jth.12845
166. Mazzucconi, M. G., Baldacci, E., Latagliata, R., ... & Chistolini, A. (2020). Anagrelide in essential thrombocythemia: Long-term efficacy and safety evaluation. Leukemia Research, 89, Article 106295. https://doi.org/10.1016/j.leukres.2020.106295